Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that co-founder and CEO Kelsey Ramsden is featured on the latest episode of the Bell2Bell podcast. The Bell2Bell Podcast offers its listeners insightful interviews with executives of companies operating in fast-moving industries. During the episode, hosted by InvestorBrandNetwork’s Stuart Smith, Ramsden provided an overview of the company’s business model and also discussed the changing regulatory and social environments surrounding psychedelic-assisted therapy. She also talked about the company’s current focus: the development of a clinical-grade, evidence-backed, science-based, AI-driven tool to enable therapists to deploy psychedelics in their clinics; patients can also use the app to assist in their care. Ideally, the app will result in better outcomes, shorter patient timeframes in clinic and even approval and unlocking insurance payments for psychedelics. “We’re a life sciences company that has two primary focal points,” said Mind Cure Health co-founder and CEO Kelsey Ramsden in the interview. “One side is digital therapeutics focused on psychedelic therapy and the other is drug development, again focused on psychedelic molecules. When we developed our model and our strategy of go-to-market. . . what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so independent of when the typical generic MDMA or psilocybin gets approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side. The side that was earliest was our digital therapeutics platform. In simple terms, what that means is that the market is going to have a lot of newly trained therapists and a lot of individuals who are new to psychedelic practice.”
To hear the full interview, visit https://ibn.fm/Ff8bw
To view the full press release, visit https://ibn.fm/4PD8d
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.